1 day Ago By Defense World Staff
Virtu Financial LLC purchased a new position in Elevation Oncology, Inc. (NASDAQ:ELEV – Free Report) in the 4th quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission. The fund purchased 63,974 shares of the company’s stock, valued at approximately $36,000.
Virtu Financial LLC owned approximately 0.11% of Elevation Oncology as of its most recent filing with the Securities and Exchange Commission. A number of other large investors also recently added to or reduced their stakes in the stock.
SG Americas Securities LLC lifted its position in shares of Elevation Oncology by 33.9% in the fourth quarter. SG Americas Securities LLC now owns 61,467 shares of the company’s stock valued at $35,000 after acquiring an additional 15,560 shares in the last quarter.
JPMorgan Chase & Co. boosted its stake in Elevation Oncology by 175.9% during the 3rd quarter.
JPMorgan Chase & Co. now owns 61,334 shares of the company’s stock worth $37,000 after purchasing an additional 39,101 shares during the last quarter. Palumbo Wealth Management LLC grew its holdings in shares of Elevation Oncology by 294.
5% during the fourth quarter. Palumbo Wealth Management LLC now owns 69,105 shares of the company’s stock worth $39,000 after buying an additional 51,590 shares in the last quarter. Barclays PLC raised its position in shares of Elevation Oncology by 302.
4% in the third quarter. Barclays PLC now owns 72,077 shares of the company’s stock valued at $43,000 after buying an additional 54,167 shares during the last quarter. Finally, State Street Corp lifted its stake in shares of Elevation Oncology by 13.
5% in the third quarter. State Street Corp now owns 1,018,026 shares of the company’s stock worth $611,000 after buying an additional 120,993 shares in the last quarter. 83.
70% of the stock is currently owned by institutional investors and hedge funds. Elevation Oncology Price PerformanceShares of ELEV opened at $0.25 on Wednesday.
The firm has a 50-day simple moving average of $0.53 and a two-hundred day simple moving average of $0.58.
The company has a debt-to-equity ratio of 0.45, a current ratio of 17.77 and a quick ratio of 17.
77. Elevation Oncology, Inc. has a 1-year low of $0.
24 and a 1-year high of $5.83. The stock has a market cap of $14.
66 million, a PE ratio of -0.30 and a beta of 1.37.
Elevation Oncology (NASDAQ:ELEV – Get Free Report) last announced its earnings results on Thursday, March 6th. The company reported ($0.18) earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of ($0.
22) by $0.04. As a group, analysts forecast that Elevation Oncology, Inc.
will post -0.84 EPS for the current year. Analyst Upgrades and DowngradesSeveral analysts recently issued reports on ELEV shares.
Citizens Jmp cut shares of Elevation Oncology from an “outperform” rating to a “market perform” rating in a research note on Friday, March 21st. HC Wainwright dropped their price target on Elevation Oncology from $6.00 to $1.
00 and set a “buy” rating for the company in a research report on Friday, March 21st. Leerink Partnrs downgraded Elevation Oncology from a “strong-buy” rating to a “hold” rating in a research report on Thursday, March 20th. Piper Sandler cut Elevation Oncology from an “overweight” rating to a “neutral” rating and dropped their target price for the company from $10.
00 to $0.70 in a report on Friday, March 21st. Finally, Leerink Partners lowered Elevation Oncology from an “outperform” rating to a “market perform” rating and reduced their price target for the stock from $9.
00 to $1.00 in a report on Friday, March 21st. Seven equities research analysts have rated the stock with a hold rating and three have given a buy rating to the company.
Based on data from MarketBeat.com, the company has a consensus rating of “Hold” and a consensus target price of $3.39.
View Our Latest Stock Report on ELEVAbout Elevation Oncology (Free Report)Elevation Oncology, Inc, an oncology company, focuses on the discovery and development of cancer therapies to treat patients across a range of solid tumors with significant unmet medical needs. The company's lead candidate is EO-3021, an antibody-drug conjugate designed to target Claudin 18.2, a clinically validated molecular target.
Featured StoriesFive stocks we like better than Elevation OncologyHow to Choose Top Rated StocksD-Wave: Multiple Use Cases Emerge Following Quantum SupremacyGrowth Stocks: What They Are, What They Are NotAmazon Falls Back to a Key Support Line: Here’s How to Play ItWhat is the Dogs of the Dow Strategy? Overview and ExamplesBuffett Trims Equities, But Still Keeps Buying This Stock.
_8.jpg?itok=wp-xhXRB)
